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Schizophrenia, Narcolepsy, and HLA-DR15, DQ6 
Alan B. Douglass, James E. Shipley, Richard F. Haines, 
Robert C. Scholten, Evelyn Dudley, and Andre Tapp 
A strong association between HLA-DR2, DQI and narcolepsy.cataplexy has been known since 
1986. In 1990 a subdivision (HLA-DRIS, DQ6) was shown to be equally associated. Nar- 
colepsy symptoms include rapid eye movement (REM)-sleep intrusion hallucinations during 
the day. Some narcoleptics may be ~o lza!lad;,atcd that they become delusional and receive 
a diagnosis of schizophrenia. Fifty.six inpatient schizophrenics and 56 normal controls were 
compared to see if there was an excess of the narcolepsy-associated antigens (NAA ) among 
schizophrenics. Patients had frequency of the NAA 3.89 times higher than controls. After a 
subset was studied by night (n = 9) and day (n = 7) polysomnography, two patients were 
found to be true narcoleptics. Their psychosis improved with treatment for narcolepsy. When 
NAA( + ) and NAA( - ) schizophrenics were compared, the NAA( + ) subgroup had significantly 
higher Brief Psychiatric Rating Scale (BPRS) scores and more hospitalizations. There were 
no effects attributable only to gender or race. We conclude that narcolepsy can simulate 
schizophrenia in some cases, and that even in nonnarcoleptic patients, the HLA-DRIS,DQ6 
antigens mark a group of severe schizophrenics that merits further study. 
Key Words: Schizophrenia, hallucinations, narcolepsy, cataplexy, HLA-DR antigens, 
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Introduction 
Matsuki (et al 1988) demonstrated in Japanese subjects 
one of the highest associations of HLA antigens with a 
given disease: HLA-DR2,DQwl with narcolepsy. This work 
has since been replicated in most other races. Only in 
blacks is the association less strong (Neeley et al 1987). 
Although some DR2-negative cases exist, the "tetrad of 
narcolepsy"--sleep attacks, cataplexy, hypnagogic hal- 
lucinations, and sleep paralysis--very strongly predicts the 
presence of HLA-DR2,DQI. Recent work (Honda et al 
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1989; Olerup et al 1990) indicates that certain "splits" or 
subdivisions of DR2 and DQI (namely DRI5 and DQ6, 
hereafter called the "narcolepsy-associated antigens," NAA) 
are themselves present in nearly 100% of patients with 
narcolepsy-cataplexy. This is also true for the haplotype 
DR15,DQ6,Dw2, although the Dw2 is not a routine an- 
tigen in most HLA laboratories. This finding permits greater 
specificity in the identification of narcolepsy by HLA test- 
ing. It should be noted that 10% or more of normal in- 
dividuals in the general population will also have the NAA, 
whereas only about 1/1000 of the general population has 
narcolepsy. Thus, although the antigens are useful for 
screening, they are not diagnostic. The modem clinical 
methods for diagnosing narcolepsy are described below. 
The intent of the present article is ~,J ~h,~w that this 
HLA pattern has implications for the diagnosis of schizo- 
phrenia as well. The literature on linkage of HLA antigens 
© 1993 Society of Biological Psychiatry 0006-3223/931506.00 
774 BIOL PSYCHIATRY A.B. Douglass et al 
1993;34:773-780 
to schizophrenia began in the early 1970s and has been 
quite controversial Many claimed associations have gone 
unreplicated, due perhaps to racial or diagnostic differ- 
ences. Because the HLA "Class II" antigens, which in- 
clude those of particular interest in narcolepsy, were dis- 
covered relatively recently, most of the research prior to 
i984 was confined to the "Class I" antigens (HLA-A, B, 
C). Tests for the HLA antigens most specifically predictive 
of narcolepsy, the NAA, only came into general use in 
1990, suggesting the need for a re-evaluation of this area. 
There have been several comprehensive reviews of the 
Class i literature (Goudemand et al 1981; Baron 1986; 
McGuffin and Start 1986). The consensus reached was 
that HLA testing was not very informative for the diagnosis 
of schizophrenia. Paranoid schizophrenic patients had a 
slightly decreased chance of showing the HLA-A ! antigen, 
but an increased chance of Ag, A28, BI8, B27 (without 
arthropathy!, and Cw4. In hebephrenic schizophrenics, A I 
and B i5 were slightly elevated, If schizophrenia is con- 
sidered as a whole, HLA-A9 and B5 were increased, whereas 
Bw35 was decreased. It has been suggested also that HLA- 
A I predicts a good antipsychotic effect of chlorpromazine 
(Reich et al 1975; Smeraldi et al 1976). 
The Class II antigens have been assessed in relatively 
few studies. A Japanese study (Miyanaga et al 1984) found 
DRw8 at increased frequency among schizophrenics. An 
Israeli study (Amar et al 1988) found no significant dif- 
ferences in DR antigens, yet the DR2 rate in schizophrenics 
in their study was double that of controls. A Scandinavian 
study (Rudduck et al ! 984) found no significant differences 
in DR. This was also true of a Dutch study (de Jongh et 
al 1982). None of the above studies examined D or DQ 
antigens. The observed "relative risk" (RR) of schizo- 
phrenia versus controls given the presence of any of the 
above Class 11 antigens is only about 2 (i,e,, doubled risk). 
This is to be compared to the RR of 70 of ankylosing 
spondylitis with HLA-B27, and the RR = 750 of nar- 
colepsy with HLA-DR2/DQI (Matsuki et ai 1988). 
Yet it is possible that the specificity of Class [I antigens 
in narcolepsy could shed light on an old controversy in 
psychiatry, namely whether some patients with narcolepsy 
are misdiagnosed as schizophrenic due to their halluci- 
nations. If so, such patients might be regarded as having 
an organic brain syndrome (narcolepsy), which causes a 
phenocopy of the schizophrenic syndrome, but through 
different biological mechanisms. 
Clinical reports (Roy 1976; Wilcox 1985) note the ex- 
istence of a schizophrenia-like illness among narcoleptics. 
These authors employed a solely clinical definition of nar- 
colepsy. Douglass and colleagues (1991) provided a re- 
view of the older literature, and described several new 
cases of "schizophrenics" with classical narcolepsy. They 
diagnosed narcolepsy objectively by HLA typing, noctur- 
nal polysomnography, and the daytime multiple sleep la- 
tency test, "MSLT" (Carskadon 1986). Their psychotic 
patients' hallucinations improved substantially when treated 
with stimulants, suggesti~g that the psychosis may have 
been due to narcolepsy rather than conventional schizo- 
phrenia. This improvement was surprising, as schizo- 
phrenic hallucination is usually worsened by stimulants, 
given that some deficit symptoms may improve (Janowsky 
and Davis 1976). 
We now report the results of a prospective pilot study, 
the goal of which was to estimate the frequency of nar- 
colepsy in a group of schizophrenic patients. This study 
was not intended to have a rigorous epidemiological de- 
sign. Rather, it was a feasibility study to establish whether 
the earlier findings could be replicated. We also sought 
any systematic clinical differences between NAA( + ) and 
NAA( - ) schizophrenics. 
Subjects and Methods 
There were 268 psychiatric inpatients with a chart diag- 
nosis of schizophrenia available for study at two VA Hos- 
pitals. Exclusion criteria were as follows [number of cases 
excluded by each criterion shown in square brackets[: any 
organic brain lesion, history of head trauma, or major 
medical illness, for example, epilepsy, diabetes meUitus 
[331; drug or alcohol abuse in the past year by DSM-III- 
R definition [51]; age greater than 65 years [12]; patient 
under guardianship or legally incompetent [54l; patient 
otherwise qualified for inclusion but refused to sign con- 
sent [50]; review of ward chart and old chart failed to pass 
DSM-III[-R criteria for schizophrenia [ ! 2]  After excluding 
the above [212] cases, a schizophrenic group consisting 
of 56 patients remained. The demographics of age, gender, 
race, number of hospitalizations, and duration of illness 
are shown in Table !. 
A race-matched HLA control group of 56 normal in- 
dividuals was obtained from the University of Michigan 
Tissue Typing Laboratory records. These were simply the 
first 47 white cases and the first 9 black cases found in a 
retrospective search of organ-donor HLA records, com- 
mencing on the date upon which the NAA antigens began 
to be tested. We did not test controls for the presence or 
absence of psychiatric illness, which was a weakness of 
the present design. Family groupings of these persons were 
known, and the 56 chosen were not related to each other. 
No formal matching of ethnic or socioeconomic status was 
done. 
The racial composition of the groups was important 
because HLA antigens associated with narcolepsy are re- 
ported to differ in the white and black populations (Neely 
et al 1986). The statistical design used was to stratify the 
control and patient groups by race, in case-control fashion. 
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T a b l e  I.  C l i n i c a l  V a r i a b l e s  in N A A (  + ) V e r s u s  N A A ( -  ) P a t i e n t s  
Variable NAA( - ), n = 36 N A A ( + ) ,  n = 20 Sig. 
Sex (M : F) 33 : 3 17 : 3 NS 
Race (black : white) 4 : 32 5 : 15 NS 
Age now 38.3 -- 7 40.1 ± 9 NS 
Years ill 14.7 ± 7 14.6 _ 8 NS 
Age at first admiss ion  23.4 _+ 5 25.4 ± 6 NS 
Number  of  hospitalizations 15.1 ± 18 21.8 _ 38 0.054 
SADS-RDC Diagnosis  (Schizophren : Schizoaffective) 14 : 22 7 : 13 NS 
AP dose (CPZ equiv . ,  mg)  769 ± 656 685 +- 723 NS 
Mood stabilizer augmentat ion (Y : N) 3 : 30 6 : 14 0.066 
TCA augmentat ion (Y : N) 4 : 29 1 : 19 NS 
BZD augmenta t ion (Y : N) 16 : 17 6 : 14 NS 
Number  totally drug-free at BPRS 3 3 NS 
Significance values shown arc from X' in comparisons involving binary variables, except where any single cell contained 
5 subjects, in which case the 2-tailed Fisher Exact Test was employed. For continuous variables, an F-test was employed. 
Those cases "totally drag free" were admitted in u psychotic state and studied in the sleep labozatory before any antipsychotic 
drags were given, Only three patients were first-break psychosis. The remainder had a relapse of their chronic psychosis. These 
results indicate that the NAA( + ) patients had a more affective, more relapsing illness with a tendency toward a schizo-affective 
diagnosis. AP = antlpsycbotic drugs: BPRS = Brief Psychiatric Rating Scale; RZD = benzodiazepine drugs; CPZ = 
chlorpromazine; TCA = tricyclic antidepressant or similarly acting drug. Augmentation = drugs used in addition to antipsy- 
~hotic drugs at any time during the cmrent hospital stay, 
All 56 of the patients agreed to a structured diagnostic 
interview by a trained research nurse. The Schedule for 
Affective Disorders and Schizophrenia (SADS-L, Endicott 
and Spitzer 1978) was employed. Those patients having 
a SADS-RDC (Research Diagnostic Criteria) lifetime di- 
agnosis "schizophrenia" or"schizoaffective" were retained 
in the study. All schizoaffective patients met the RDC's 
*'mainly schizophrenic" criteria. Most patients were chron- 
ically hospitalized and taking antipsychotic drugs at the 
time of the SADS interview, whereas others were newly 
admired and drag-free. Diagnosis and chlorpromazine dose- 
equivalence of antipsychotic medication (Knoben and An- 
derson 1988) are shown in Table I. At the time of SADS 
interview, all patients were also rated on the Brief Psy- 
chiatric Rating Scale (BPRS, 18-item version), which was 
scored I-7 COverall and Gorham 1962). Finally, the Sleep 
Disorders Questionnaire (SDQ, Douglass et al 1990, 1992, 
1993) was administered to obtain an assessment of the 
clinical symptoms of sleep pathology, particularly nar- 
colepsy. The SDQ "NAR" scale provides a percentile score 
that compares the respondent to a population of narcolep- 
tics diagnosed in a sleep laboratory. 
A blood sample was analyzed for HLA Class II antigens 
using commercial tissue-typing trays at the University of 
Michigan Tissue Typing Laboratory. The research pro- 
tocol, as approved, permitted only NAA(+) patients to 
be taken off antipsychotic drugs for sleep studies. The 
rationale was that these were the only patients likely to be 
narcoleptic, and therefore likely to benefit from the pro- 
tocol. A more rigorous design would have been to test an 
equal number of patients with and without the NAA. 
All 20 NAA( + ) patients were eligible to proceed to 
the sleep study. For reasons discussed below, only nine 
completed them. First, their regular antipsychotic dosage 
was tapered at a rate of 10 mg per week (haloperidol 
equivalent) to a minimum of 10 mg/D. All medications 
were then stopped for 2 weeks to enable sleep laboratory 
testing. 
The nocturnal polysomnogram (NPSG) included mea- 
surement of electroencephalogram (EEG), electrooculo- 
gram (EOG), electromyogram (EMG), electrocardiogram 
(EKG), oximetry, respiratory airflow, and respiratory el- 
tort. The next day, an MSLT was performed to screen 
for narcolepsy. 
Those NAA(+ ) patients whose sleep laboratory re- 
suits did not confirm a diagnosis of narcolepsy terminated 
the study at this point (n = 7). 
The two NAA(+) patients whose sleep laboratory 
results confirmed classical narcolepsy, and one with 
equivocal findings, received a double-blind trial of the 
mild central nervous system (CNS) stimulant magnesium 
pemoline (CYLERT, Abbott Laboratories, North Chi- 
cago, Illinois) versus placebo in an A-B design that 
entailed 1 week of each condition and weekly BPRS 
ratings. A re-examination of the narcoleptics' medical 
charts revealed that some years prior to our contact, both 
had been suspected of having narcolepsy on the basis of 
clinical symptoms, and had been also psychotic. Al- 
though both had been treated briefly and unsuccess- 
fully with amphetamines, their management had been 
exclusively psychiatcic for some years prior to our 
contact. 
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Statistical Tests 
To assess whether th~='e was a significantly greater fre- 
quency of NAA(+ ) cases among the 56 patients versus 
the 56 control subjects, a ×2 test was performed. An a 
priori hypothesis of an excess of the NAA among schizo- 
phrenics was suggested by the results of a previous study 
(Douglass et al 1991). It is customary to use a formula 
to inflate the X 2 required for significance (Svejgaard and 
Ryder 1977) to reduce Type II statistical error in HLA 
studies involving numerous HLA antigens. This proce- 
dure is not required in the case of one or two HLA 
antigens, which are the subject of an a priori hypothesis. 
Our ×' is therefore calculated without the inflation factor, 
Another X 2 test was performed on all !12 subjects pooled, 
NAA status versus race, to see if there was an HLA 
pattern due to race. 
Considering only the 56 subjects in the patient group, 
tests of 2 x 2 tables (2-tailed Fisher Exact Test, or X 2 as 
appropriate) were performed on: NAA status ( + / - ) ver- 
sus diagnostic subtype (schizophrenia or schizoaffective): 
race versus diagnostic subtype', gender versus race; and 
gender versus diagnostic subtype. 
To assess whether NAA(+) marked an identifiable 
subsyndrome of schizophrenia, a multivariate analysis of 
variance (MANOVA, SAS-PC version 6.03) was per- 
formed. The categorical variables Race, Sex, and NAA 
status were used in a 3-way MANOVA design. The 
analysis was done twice, once on all 56 subjects, and 
again with the three narcoleptic patients removed from 
the NAA( + ) group to see if they alone were responsible 
for any significant differences. Continuous variables in 
the model included the BPRS score, demographic vari- 
ables (age, age at first illness, years ill, number of hos- 
pitalizations), and six scoring subscales of the SADS 
C4. Suicidal ideation and behavior, 7. Delusions and 
hallucinations, 9. Impaired functioning, 13. Global As- 
sessment Scale, worst period, 14. Extracted Hamilton 
[depression scale], 23. Social Functioning," Endicott and 
Spitzer 1978). Before entry into MANOVA, each con- 
tinuous variable was tested for normality of distribution 
by the SAS procedure "proc univariate" and Wilk's W- 
Test for normality (Royston 1982L Variables that were 
obviously skewed, or failed to attain W -> 0.85, were 
transformed to normalize. Log~o transform was used for 
"number of hospitalizations" and the SADS "Thought 
disorder" subscale; legit transform was used for SDQ 
percentile subscales. 
Other categorical variables were gathered to possibl~- 
differentiate the NAA( + ) versus the NAA(-  ) group. 
These included whether the ward psychiatrist employed 
an antipsychotic augmentation strategy (antidepressants, 
benzodiazepincs), or mood stabilizers (lithium or carba- 
mazepine). These data were analyzed by two-tailed Fisher 
Exact Test, or ×2, as appropriate, depending on whether 
the smallest cell was -< 5. 
The drug trial involved only three patients, so statis- 
tical treatment was not attempted. 
R e s u l t s  
In the patient group it was found that 20/56 possessed both 
NAA. Also, all 20 of these patients were positive for HLA- 
DR2,DQI although the more specific NAA are the focus 
of this article. One other patient had HLA-DRi5 without 
DQ6. He was placed in the NAA( - ) group. In the control 
group, 7/56 had NAA, approximately the rate in the gen- 
eral population (Bauer et al 1984). Thi~ difference in ob- 
served NAA frequencies was significant (X 2 = 8.25, 
Of = 1, p < 0.004), and represents an RR = 3.89 (95% 
confidence limits: 2.78-5.43). 
There was no effect of race alone on the frequency of 
NAA (X 2 = 0.998, df = l, p = 0.32) among all 112 
subjects pooled. 
Patients showed no significant difference in the fre- 
quency of diagnosis versus NAA status (X 2 = 0.83, 
df = 1, p = 0.77); race versus NAA status (Fisher Exact 
p = 0.26; diagnosis versus race (X' = 0.221, df -- l, 
l' = 0.64); diagnosis versus gender (Fisher Exact p = 
1.00); nor sex versus race (Fisher Exact, p--0.35) see 
Table !. These data were considered for a (multivariate) 
categorical log-linear model analysis, but the n was not 
sufficient. They are reported as a series of univariate cat- 
egorical tests, but the possibility of Type-ll error must be 
kept in mind. 
Of the 20 NAA(+) patients, nine completed NPSG 
sleep studies, and only seven completed MSLT studies. 
One patient had a significant psychotic relapse on with- 
drawal of medications and so could not complete the pro- 
tocol. Some accepted the NPSG but would not follow 
instructions for the MSLT. Table 2 shows the NPSG 
mean values for the nine patients, and is subdivided 
into the 6 NAA(+)  patients who had a negative MSLT 
versus the three with a positive MSLT. Considering 
again the possibility of Type-ll error, these results 
show very little difference in the nocturnal sleep of 
these NAA( + ) subgroups. 
Two of these 20 patients (or 2/56 = 3.8% of all pa- 
tients, 95% confidence limits: 0.0-1 !.4%) proved to have 
the clinical syndrome of classical narcolepsy (cataplexy 
witnessed by us, sleep attacks in meetings, sleep paralysis, 
hypnagogic hallucinations). In the MSLT studies (Table 
3), they both had four or more sleep-onset REM (SOREM) 
naps and pathologically short mean sleep latencies (MSL) 
such that the clinical diagnosis of narcolepsy was con- 
firmed objectively. A third patient had thee SOREM naps 
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Table 2. Nocturnal Sleep Results of NAA( + ) Patients 
6 NAA( + ), 
Nocturnal sleep Patient 1 Patient 2 Patient 3 Mean of Nonnarcoleptic cases 
measure (narcolepsy, NAA + ) (narcolepsy, NAA + ) (equivocal, NAA + ) Patients 1-3 (mean - SD) Significance 
TRP 448 329 372 383 360 _ 42 0.61 NS 
SL 15 6 61 27.3 92.7 - 58 0.07 NS 
ALT2 29 20 1 16,7 20.5 "*- 24 0.89 NS 
# Wakes 16 8 5 9,7 3,2 - 3,5 0.04 
WASO 135 103 6 81.3 30.5 _ 52 0.30 NS 
TSA 297 220 305 274 230 ± 78 0.44 NS 
SE (tsa/trp) 66.3 66.9 82.0 71.7 64.4 +_ 22 0.89 NS 
% STAGE I 66.7 47.3 40,3 51.3 38.1 ± 25 0.44 NS 
% STAGE 2 23.6 41.8 41.0 35,5 47.0 ± 12 0,30 NS 
% REM 9,4 10.9 18.7 13,0 22,6 ± 6.5 0.051 
% REM 2 4 3 3 2,6 ± 0,8 0.52 NS 
periods 
EL 302 1.0 71 124,7 41.6 ± 102 0.55 NS 
RLMA 198 1.0 70 89.6 40.0 ± 61 0.37 NS 
RT 28 24 57 36,3 58,6 ± 20 0,10 NS 
RA (units) 74 30 43 49 68.2 ± 19 0,18 NS 
RD (RA/RT) 2,6 1.2 0,7 1,5 1.40 ± 0.75 0,86 NS 
Detailed results of Nocturnal Poly~mnography (NPSG) on the three patients who had both HLA-DRI5,DQ6 (i,e,: NAA + ), and clinical symptoms of narcolepsy, 
Patients I and 2 had the full tetrad with witnessed cutaplexy. Patient 3 was delusional, had visual hallucinations, no cataple~ty, and an equivocal MSLT, A further 6 
NAA( + ) patients without clinical or MSLT evidence of narcolepsy ate shown for comparison. Because of nonGaussian distributions and small n, variables were compared 
by the nqnparametric Kmskal-Wallis Test, Groups: the 3 NAA( + ) versus the 6 NAA( - ) cases. See text for discussion of these results as they affect the validity of the 
MSLT. 
TRP = total recording period; SL = sleep latency (number of minutes from. lights-out until 90 sac of stage 1; or 30 sac of slage 2 sleep); ALT2 = rain awake in 
last 2 hr of recording; #WAKES = number of wakes of 2 rain or greater during the night; WASO -- minutes of wake after sleep onset; TSA = time spent asleep (rain)'. 
SE = sleep efficiency; %Stage I . . • %Stage 2 -- light sleep expressed as a percentage of TSA; %REM = rain Rapid Eye Movement sleep as percentage of TSA; 
RL = rain from sleep onset to first observed REM sleep epoch; RLMA = "RL minus awake"; RT = REM time in rain', RA -- REM activity (Kupfer units)', RD -- 
REM density 
Table 3. Daytime MSLT Results 
Variable Patient ! Patient 2 Patient 3 
All other 
NAA( + ) 
patients, 
n = 4  
Nap # I :  SL (RL) 1.0 (1.5) 3.5 (3,5) 17 (16) 
Nap #2:  SL (RL) 3.5 (4.0) 3,0 (2,0) 17 (12) 
Nap #3:  SL (RL) 1.0 (4.0) 2,0 (7.0) - -  ( - - )  
Nap #4:  SL (RL) 2.0 (4.0) 2.5 (0,5) I0 (10) 
Nap #5:  SL (RL) 3 .0(7 ,0)  - -  ( - - )  - -  ( - - )  
MSL (MRL) 2, I (4.1) 2,8 (3,3) 14,6 (12.6) 
#SOREMs 5/5 4/4 3/5 
21,0 ( - - )  
0/5 
Results of Multiple Sleep Latency Test (MSLT), done the day after the NPSO 
of Table 1. Standard 5 nap protocol. All latencies are shown as minutes, SL = 
Sleep Latency; RL = REM sleev latency following SL; MSL -- mean sleep latency 
in the naps; MRL = mean RUM sleep latency in naps; SOREMs -- number of 
sleep onset REM periods. Results for patients t and 2 suggest classical narcolepsy. 
Patient 3 has SOREM naps as do the natcoleptics, but a normal MSL, which is 
atypical for narcolepsy, 
but a near-normal MSL and no witnesGed cataplexy despite 
giving a history of partial cataplexy, therefore he was given 
a diagnosis of"equivocal narcolepsy." All three were men, 
and carried a SADS-RDC lifetime diagnosis of "schi- 
zoaffective, mainly schizophrenic type" and a DSM-III-R 
diagnosis of paranoid schizophrenia. 
Obstructive sleep apnea (OSA) was also present in pa- 
tients # 1 and #2. Results for patient #1: number of apneas 
= 106, hypopneas = 82, apnea-hypopnea index = 38, 
lowest arterial oxygen saturation (SaO2) desaturation -- 
70%, mean duration of events = 20 sec. Results for patient 
#2: number of apneas = 116, apnea-hypopnea index -- 
61, lowest SaO2 desaturation 72%, mean duration of events 
= 15 see. These patients were offered continuous positive 
airway pressure (CPAP) treatment for apnea before their 
MSLT study. Patient #1 refused for delusional reasons, 
whereas patient #2 accepted. Thus #1's MSLT shows the 
effect of apnea plus narcolepsy, whereas #2's shows only 
the effect of narcolepsy. Two years later, #1 accepted 
CPAP in addition to narcolepsy treatment, and his clinical 
condition improved further. 
The BPRS scores of these three patients during the drug- 
free baseline, placebo, and pemoline conditions were as 
follows: #1--68, nil, 36; #2--64, 67, 44; #3-29, 37, 32, 
Pemoline therefore caused a substantial reduction in BPRS 
score in the 2 classical narcoleptics, but not in the equiv- 
ocal case #3.  
The MANOVA results were significant for the NAA 
dimension, but not for gender or race (Table 4). Subse- 
quent one-way ANOVAs showed significant differences 
in the pattern of clinical variables between NAA( + ) and 
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Table  4. O n e  W a y  A N O V A s  fo l lowing  M A N O V A  
NAA( - ) NAA( + ) Significance Significance 
Variable n = 36 n = 20 (n = 56) (n = 53)* 
BPRS total score 
Suic,dality (SADS scale 4) 
Hallucination/delusion (SADS 7) 
Impaired functioning (SADS 9) 
GAS at worst (SADS 13) 
Derived Hamilton (SADS 14) 
Social Function (SADS 23) 
32.8 --- 9.7 46.9 -+ 15 0.0008 0.0024 
2.72 ± 2.4 4.20 +- 3.8 0.02 0.016 
38.2 - 8.5 36.4 +- 9.8 NS NS 
5.53 -4- 2.2 6,67 ± 2.2 0.06 0.045 
33.7 +_ 6.3 29.13 _ 12 NS NS 
17.2 ___ 7.4 17.53 - 8.7 NS NS 
19.0 --- 4.3 19.8 _ 4.0 NS NS 
A three-way multivariate analysis of variance (MANOVA, NAA x Race x gender) was performed on 10 variables which 
inspection suggested would demonstrate differences between NAA( + ) and NAA( - ) groups. These included all the variables in 
Table 4, plus "CPZ equivalent dose," "Years ill." and "Number of hospitalizations" from Table 1. MANOVA was significant, 
hut only for the dimension "NA A Status." ( F = 2.49. df = 11/27. p -- 0.026) Dimensions "Sex" and "Race" were not significant. 
One-way ANOVAs were then pert'armed on the variables underlying the NAA dimension of the MANOVA. only. to identify the 
source of significance. This table shows all subjects (n = 56). When the three narcoleptic subjects were removed from the 
NAA( + ) group (*tt = 53). the significance pattern remained the same (MANOVA for NAA: F -- 3.35. p -- 0.0047), indicating 
that these findings also apply to the NAA( 4. ) group as a whole, 
NAA(- ) patient subgroups. When the three narcoleptics 
v,ere removed from the data and the statistic done again, 
the pattern of significance was not altered (Table 4). These 
results suggest that the NAA(+) group as a whole, not 
just the diagnosed narcoleptics, had a more symptomatic 
form of schizophrenia as measured by the BPRS. Com- 
paring Table l with Table 4 suggests that the NAA( + ) 
group had a more affective form of schizophrenia with 
higher numbers of hospitalizations, greater use of mood 
stabilizers to augment their antipsychotic drugs, more su- 
icide attempts, and more impaired functioning. Although 
this would seem to suggest a schizoaffective diagnosis, 
the frequency of SADS-RDC diagnoses did not differ sig- 
nificantly (Table I). 
The SDQ "NAR" scales of patients #1 -#3  were 99, 
98, 72 percentile, respectively. This indicates that their 
responses resemble those of the most severe nonpsychotic 
narcoleptics in the SDQ reference group. With these three 
patients removed, the NAA( + ) group percentile mean on 
NAR scale was 38.1 +_ 31, and the NAA(-)  group 33.5 
- 33 (NS by t-test). 
Patients # i-3 have been treated in follow-up for 2 years 
with lithium carbonate and pemoline but no antipsychotics 
have been required. Symptoms of auditory, visual, and 
tactile hallucinations improved within a week. Those hal- 
lucinations remaining were obviously hypnagogic, occur- 
ring when the patient missed medication or was overtired. 
Interestingly, patients no longer elaborated them into de- 
lusional themes. Delusit~al paranoid ideas and disorgan- 
ized thought also disappeared, but over several months. 
On their medications for narcolepsy and mood stabiliza- 
tion, (and CPAP for sleep apnea in patients # l and 2), 
none of the three would currently meet criteria for a di- 
agnosis of schizophrenia. 
Discussion 
These results suggest that classical narcolepsy may have 
been involved in the etiology of the psychosis of two 
patients (3.6%) in our sample of patients hospitalized for 
schizophrenia. In addition, there was one equivocal case 
of narcolepsy found who had REM intrusion but not ob- 
jective excessive sleepiness on MSLT. The psychotic 
symptoms in these three patients resolved with stimulant 
treatment, whereas previous treatment with antipsychotic 
drugs had been ineffective. 
A positive MSLT is central to the diagnosis of narco- 
lepsy. Was there sufficient nocturnal REM sleep to validate 
these MSLTs? The nocturnal sleep of the patients with 
narcoleptic MSLTs, although poor in quality and duration, 
was not significantly different from the other schizophrenic 
patients who had normal MSLTs (Table 2), suggesting 
that these were not false positives. None of the NPSG 
REM variables was significantly different. 
Although some narcolepsy patients have a short noc- 
turnal REM-onset latency, as do many depressed patients 
(Kupfer 1976), this has only been reported recently in 
schizophrenics (Kumar et al 1985; Zarcone et ai 1987; 
Tandon et al 1992). The repotted iatencies are as short as 
those commonly reported for depression. Other schizo- 
phrenics have a nocturnal REM latency no different from 
that of normals (Kempenaers et al 1988; Reich et al 1975). 
It will be interesting to see whether some "schizophrenics" 
with short nocturnal REM latencies prove to have daytime 
MSLT REM latencies which are so short as to meet the 
criteria for narcolepsy. If so, they may be not schizo- 
phrenic at all, but narcoleptic, as were some patients in 
this study. Such schizophrenic patients could be screened 
for narcolepsy by means of the NAA, but these have the 
disadvantage of costing about $300 per patient. One ad- 
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vantage is that they can be done while the patient is still 
on antipsychotic medications, unlike a sleep study. In the 
absence of HLA-DRI5,DQ6 a patient is extremely un- 
likely to have narcolepsy as a contributing cause of psy- 
chosis. 
The face validity of the SDQ "NAR" scale to screen 
for narcolepsy among schizophrenics receives strong sup- 
port in these three cases. More support for the narcoleptic 
diagnosis comes from our observation of gross hypnagogic 
hallucinations during naps in two of the narcoleptic pa- 
tients. Both would fall asleep in group therapy, then par- 
tially awake in a confused state in which they were talking 
out of context, apparently to their hypnagogic hallucina- 
t ions-very  "schizophrenic" when seen on a ward of 
schizophrenics, yet also quite common among nonpsy- 
chotic narcoleptics in the waiting rooms of sleep disorder 
clinics! Also, both had "falling attacks" (cataplexy) during 
times of sudden emotion such as anger, laughter, or sur- 
prise. 
A major limitation of this study is that we did not obtain 
sleep studies in the N A A ( -  ) patients. This needs to be 
done in future to control fully for the possibility that a 
"narcoleptic" MSLT is present in some psychotic patients 
who are taken off antipsychotics for 2 weeks. 
Obstructive sleep apnea was present in two of our nar- 
coleptics. It may be that this is a coincidental finding. 
Alternatively, it may be that apnea is partially responsible, 
in concert with narcolepsy, for tile induction of an organic 
brain syndrome predisposing to visual hallucinosis. In fu- 
ture cases, there should be a full reassessment of the psy- 
chiatric and polysomnographic status after resolution of 
the apnea but before the narcolepsy is treated with stim- 
ulants. 
The significant mean BPRS elevation in the NAA( + ) 
patients versus NAA(-  ) patients was unexpected. Al- 
though the possibility of Type !1 error must be considered, 
it seems that there was a tendency for the NAA to be 
associated with greater symptom severity: greater history 
of suicidal intent, suicidal behavior, and more hospital 
admissions. This also suggests an affectively laden, re- 
lapsing illness. Alternatively, these findings could mean 
that members of the NAA( + ) group were for some reason 
less responsive to their particular antipsychotic drugs over 
the years. There were proportionally more SADS-RDC 
schizoaffectives among the NAA( + ) group, although this 
difference was not statistically significant. Further support 
for a connection between NAA( + ) status and a schizoaf- 
fective clinical picture is that the ward psychiatrists chose 
to augment their treatment of these patients with mood 
stabilizing medication at much higher rates than they did 
with N A A ( - )  schizophrenics, and that difference ap- 
proached significance. They also used less tricyclic anti- 
depressants (TCA) and benzodiazepine (BZD) medications 
with the NAA( + ) group. 
All of these findings must be regarded as preliminary 
until they can be replicated in a larger sample. 
in summary., this study suggests that narcolepsy and 
sleep apnea can be occult diagnoses in some patients who 
appear at first to have schizoaffective disorder with prom- 
inent psychotic symptoms, unresponsive to the common 
antipsychotic medications. The follow-up of our three pa- 
tients treated with pemoline and lithium has now passed 
2 years without a psychotic relapse, which represents a 
major improvement in their condition. The benefit from 
lithium is interesting, it may suggest that the patients had 
an underlying diagnosis of bipolar disorder that was ob- 
scured by the cognitive and hallucinatory symptoms of 
sleep apnea and narcolepsy, respectively. In this scenario, 
persistent abnormalities of thought plus persistent hallu- 
cinations caused by the sleep disorders may have resulted 
in a diagnosis of RDC schizoaffective schizophrenia by 
mistake. 
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